Saturday 17 October 2026
Export KAPA’s income statement to Excel — free account
Kairos Pharma, Ltd.
KAPA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 25.0% and free cash flow fell 25.7%, each against the same quarter a year earlier.
0.60
0.07
−10.45%
Follow KAPA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (113.96%) | (93.84%) | (97.99%) | (92.07%) |
+8 more TTM periods Free account |
|
| (104.32%) | (85.36%) | (88.51%) | (77.46%) | ||
ROIC |
(322.91%) | (369.94%) | (346.52%) | (339.63%) | |
Return on Tangible Assets |
(199.55%) | (145.54%) | (104.99%) | (80.94%) | |
Free Cash Flow per Share |
(1.30) | (1.25) | (1.31) | (1.44) | |
Free Cash Flow |
(3.97) | (3.76) | (3.44) | (4.16) | |
| Other line items | |||||
Cash ROIC |
(54.92%) | (39.14%) | (29.47%) | (29.10%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.68 | 0.64 | 0.63 | 0.82 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.30) | (1.25) | (1.31) | (1.44) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates